JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Elenco Azioni・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

21.52 -0.6

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.43

Massimo

21.64

Metriche Chiave
By Trading Economics
Entrata	-14M -50M
Vendite	12M 128M
Margine di Profitto	-39.506
Dipendenti	1,784
EBITDA	-17M -48M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+63.74% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	261M 2.5B
Apertura precedente	22.12
Chiusura precedente	21.52

Notizie sul Sentiment di mercato

By Acuity

43%

57%

135 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

28.13 / 31.12 Supporto e resistenza

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 mag 2026, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 mag 2026, 20:40 UTC

Acquisizioni, Fusioni, Takeovers

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 mag 2026, 18:37 UTC

I principali Market Mover

Senseonic Shares Slide on Underwritten Offering Price

1 mag 2026, 16:46 UTC

I principali Market Mover

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 mag 2026, 19:57 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 mag 2026, 15:24 UTC

Utili

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 mag 2026, 12:46 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 mag 2026, 08:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 mag 2026, 20:42 UTC

Utili

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 mag 2026, 19:33 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 mag 2026, 19:33 UTC

Discorsi di Mercato

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 mag 2026, 19:18 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 mag 2026, 19:13 UTC

Discorsi di Mercato

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 mag 2026, 18:36 UTC

Utili

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 mag 2026, 18:35 UTC

Utili

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mag 2026, 18:28 UTC

Utili

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 mag 2026, 18:27 UTC

Discorsi di Mercato

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 mag 2026, 18:14 UTC

Acquisizioni, Fusioni, Takeovers

Barclays Completes Acquisition of Best Egg

1 mag 2026, 18:04 UTC

Utili

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 mag 2026, 17:43 UTC

Discorsi di Mercato

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 mag 2026, 17:37 UTC

Discorsi di Mercato

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 mag 2026, 17:30 UTC

Discorsi di Mercato

Utili

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 mag 2026, 17:28 UTC

Discorsi di Mercato

Utili

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 mag 2026, 17:21 UTC

Discorsi di Mercato

Utili

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 mag 2026, 17:19 UTC

Discorsi di Mercato

Principali Notizie su Eventi

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 mag 2026, 16:38 UTC

Discorsi di Mercato

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 mag 2026, 16:23 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

63.74% in crescita

Previsioni per 12 mesi

Media 35.27 USD 63.74%

Alto 47 USD

Basso 21.8 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

28.13 / 31.12Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

135 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.